Safety, Tolerability and Effectiveness of Nuedexta in the Treatment of Pseudobulbar Affect (PBA)

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 367 participants.

Also called NCT01799941

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 367 participants (enrolled count) (from the registry)
Sponsor
Avanir Pharmaceuticals (from the registry)
Registry
  • NCT NCT01799941
Other papers using this trial's data
  • PRISM II: an open-label study to assess effectiveness of dextromethorphan/quinidine for pseudobulbar affect in patients with dementia, stroke or traumatic brain injury BMC neurology, 2016-06-09 DOI, PubMed 27276999, PMC4899919 PubMed links an erratum for this paper. Erratum: PMID 27590297 In the PMC Open Access subset under CC BY.
  • Safety, Tolerability, and Effectiveness of Dextromethorphan/Quinidine for Pseudobulbar Affect Among Study Participants With Traumatic Brain Injury: Results From the PRISM-II Open Label Study PM & R : the journal of injury, function, and rehabilitation, 2018-10 DOI, PubMed 29477412

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01799941. Allocation not applicable; no masking; primary purpose treatment. Start 2013-02 (registry gives no type); primary completion 2015-05 (actual). Results posted on 2017-03-15.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Safety, Tolerability and Effectiveness of Nuedexta in the Treatment of Pseudobulbar Affect (PBA)
Acronym
PRISM II
Condition
Pseudobulbar Affect (PBA)
Condition
Stroke
Condition
Dementia
Condition
Traumatic Brain Injury (TBI)
Intervention (Drug)
Nuedexta (DM 20 mg/Q 10 mg)
Lead sponsor
Avanir Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct01799941
Content hash
d388a239ae4fc03d124052f2fd7bc40fa81386cb3254b0ca8ed7249a0dc18613